Proteoglycan 4 (PRG4), first identified in synovial fluid, is an extracellular matrix structural protein in the joint implicated in reducing shear at the cartilage surface as well as controlling adhesion-dependent synovial growth and regulating bulk protein deposition onto the cartilage. However, recent evidence suggests that it can bind to and effect downstream signaling of a number of cell surface receptors implicated in regulating the inflammatory response. Therefore, we pose the hypothesis: Does PRG4 regulate the inflammatory response and maintain tissue homeostasis? Based on these novel findings implicating PRG4 as an inflammatory signaling molecule, we will present and discuss several hypotheses regarding potential mechanisms by which PRG4 may be able to regulate inflammation. If future studies can demonstrate that PRG4 is a potent inflammatory mediator, this will change current paradigms in the musculoskeletal and ophthalmological fields regarding the how the inflammatory microenvironment is regulated in these tissues and potentially others.
Introduction
Proteoglycan 4 (PRG4)/Lubricin is a mucin-like glycoprotein that was identified and characterized in synovial fluid (SF) during an investigation of SF lubricating mechanisms between articular cartilage surfaces under load. [1] PRG4 was later found to be expressed and secreted by the cells that line the joints, synoviocytes and chondrocytes; intervertebral disc; temporomandibular joints; lung, liver, heart; the eye lid-corneal interface and pericardium membrane. [2] [3] [4] [5] [6] [7] [8] [9] Mutation in the PRG4 gene causes an autosomal recessive disease called camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome which is characterized by synovial hyperplasia: a condition where overgrowth of synoviocytes slowly damage synovial joints by interfering with normal exchange of nutrients to waste and by the secretion of proteases. [10] These patients (%30%) also present with joint deformity and thickening/fibrosis of the pericardium. [10] Prg4 À/À mice also present with changes to the articular cartilage, but also present with increased damage to the ocular surface staining, thus suggesting that PRG4 may play a key role in ocular surface boundary lubrication, and may prevent corneal damage under normal homeostatic conditions. [5, 11] Furthermore, in vivo preclinical animal studies and ex vivo studies on human tissues have demonstrated that altered expression and/or function of PRG4 has been associated with acute and chronic diseases including osteoarthritis (OA), [12] rheumatoid arthritis (RA), [13] Sjogren syndrome, [14] atherosclerosis, [15] and pericarditis. [7] In most of these previous studies, the function by which PRG4 promotes tissue homeostasis or its absence contributes to increased tissue damage has been through a reduction in friction. The ability of PRG4 to reduce friction between biological surfaces is highly dependent on its unique structure, which is discussed in the following sections. Originally perceived solely as a lubricating molecule in these diverse tissues, we suggest that in addition to reducing friction between biological surfaces a growing body of literature suggests that PRG4 has the ability to interact with immune cells. This implies that PRG4 may play key roles in immunity and/or the regulation of the inflammatory response. [15] [16] [17] [18] [19] In this manuscript, we introduce known lubrication functions of PRG4 and present a hypothesis supported by the literature that PRG4 acts a buffer in the inflammatory response.
Does PRG4 Have the Ability to Buffer the Inflammatory Response?
Inflammation is a self-defence mechanism involving innate and adaptive immune systems against harmful stimuli but can cause damage when it persists longer than necessary as it contributes to tissue injury oxidative stress, remodeling of the extracellular matrix, angiogenesis, and fibrosis. [20] PRG4 interacts with immune cells effectively coating these cells so they do not respond to "background" levels of pro-inflammatory cytokines. Recent evidence has demonstrated that PRG4 is implicated in inflammatory diseases in additional ways than through its sole lubrication properties. When a pro-inflammatory response is required (e.g., after injury), PRG4 is shed from immune cells allowing propagation of the inflammatory response. PRG4's ability to buffer the inflammatory response may also be affected through cleavage by proteases and we hypothesize that these PRG4 cleavage products may be more active in inflammatory signaling than the full-length protein. We also hypothesize that mechanisms by which PRG4 reduces friction are distinct and additive from regulation of the inflammatory response (e.g., not simply that the loss of PRG4 leads to increased friction which in turns leads to a pro-inflammatory response). In the following sections we will provide support for this hypothesis by discussing existing literature that implicates PRG4 as an inflammatory mediator while also proposing experiments to better characterize the role of PRG4 as a "buffer" of inflammation.
The Structural Importance of Glycosylation for PRG4
There are multiple types of proteoglycans implicated in various aspect of biology and the largest class is the small leucine-rich proteoglycans (SLRPs) counting 18 distinct gene products and additional splice isoforms and processed forms. [21] SLRPs are characterized by a central region constituted of leucine-rich repeats. A hallmark of SLRPs is their ability to interact with other proteins and they share several similar binding partners including many types of collagens, receptor tyrosine kinases, innate immune receptors. [21] In contrast to SLRPs, PRG4 has been investigated to a lesser extent and may be considered a part-time proteoglycan. Human PRG4 contains 1404 amino acids and is composed of different domains of functional and structural importance encoded by PRG4 gene. It contains 12 exons with exon 6 being the extensively glycosylated mucin-like central domain flanked by globular, cysteine rich N-and Cterminal domains. [4] Alternative splicing of exons (exons 2-5) results in different isomers of PRG4. [22, 23] The amino acid sequence of PRG4 across species tend to be highly conserved. [4] In different tissues/fluid within the body, PRG4 can be found as monomers, disulfide bonded dimers, and higher order multimers (potentially purely covalent complexes or not) with reported molecular weights ranging from 223 to 1493 kDa. [24] However, it remains unknown if these different protein conformations of PRG4 (monomers or covalent complexes) have overlapping or distinct biological function. While in vitro studies have examined the importance of PRG4's higher order structure on its lubricating properties, [25] additional in vivo experiments are needed to elucidate if the quaternary structures of PRG4 have physiological roles or only the monomer is sufficient. PRG4 dimers have been detected but a better characterization is needed and whether or not they impact lubrication or cell signaling will need to be demonstrated as well in vivo. The addition of recombinant PRG4 covalent complexes or a mutant form of PRG4 unable to form covalent complexes to Prg4 À/À mice would be a way to test the importance of PRG4 protein conformation and/or high order PRG4 conformation in both lubrication and signaling mechanism. The central mucin-like domain of PRG4 has been the most rigorously studied and is characterized by the repeating motif (KEPATT) that makes up about 50% of the mass of PRG4 due to the O-linked oligosaccharides. [26] The core 1 O-linked oligosaccharides are composed of Galβ1-3GalNAcα1 and the sialylated core 1 is composed of Neuα2-3Galβ1-3GalNAcα1 and Neuα2-3Galβ1-3(NeuAcα2-6) GalNAcα1. Core 2 structures are composed of NeuAcα2-3Galβ1-3(NeuAcα2-3Galβ1-3/ 4GlcNAcβ1-6)-GalNAcα along with small proportion of sulfated core 2 oligosaccharides found in low abundance. The presence of sialylated and sulfated structures may enable PRG4 to bind to neutrophils through L-selectin. [19, 27] However, the epitopes where L-selectin binds to the mucin domain of PRG4 have not yet been fully characterized [19] but could be characterized using surface plasmon resonance. Central to our hypothesis is that glycosylation is believed to play an important role for interaction of PRG4 with immune cells. [19, 27] However, glycosylation in the mucin domain is also found to be critical for lubricating functions of PRG4 as de-glycosylation is directly linked with diminished lubrication. [28, 29] While it would be extremely difficult to experimentally dissect the signaling versus mechanical properties of glycosylation in the mucin domain, changes in O-glycosylation of this domain is associated with arthritis. [27, 30] One way we could test the difference between the lubrication and signaling role of PRG4 would be through the injection of tagged recombinant N-terminal, mucin, and C-terminal domains alone of PRG4 within the joints of Prg4 À/À mice subjected to a destabilization of the medial meniscus (DMM) surgical model of osteoarthritis. Using quantitative phospho-proteomics, [31] the changes in cell signaling could be characterized and a pendulum test could be performed to assess the changes in lubricating properties after altering PRG4 expression. [11] The N-terminal domain and the somatomedin (SMB)-like domain are thought to facilitate disulfide bonds leading to multimerization of PRG4. [29, 32] With the C-terminal hemopexin-like domain being essential for PRG4 to interact with CD44, a cell adhesion protein ubiquitously expressed, [33] and extracellular matrix proteins such as galectin-3 [34] ; cartilage oligomeric matrix protein; type II collagen and fibronectin. [32] Additional experiments exploring and dissecting the roles of each individual domain of PRG4 as proposed above will aid elucidating the multiple roles played by PRG4 in lubrication, inflammation and tissue homeostasis. Because of its near ubiquitous expression in adult tissues, PRG4 has been associated with multiple physiological processes and disease mechanisms. PRG4 expression is also thought to be of importance during development as PRG4 expression in the joint is undetectable before joint cavitation, yet increases as the joint develops. [35] However, its role in development is not well understood as Prg4
À/À mice demonstrate no obvert phenotype at birth; but develop numerous phenotypes with aging. The lack of a conditional Prg4 À/À mouse has hampered our ability to directly test the role of PRG4 in specific cell types and thereby define molecular mechanisms and unravel functional roles that PRG4 is involved in during development and/or adulthood. The generation of cell type specific Prg4 inducible knockout mouse would greatly contribute to the investigation of tissue specific roles of PRG4. Hence, our knowledge of PRG4 function remains highly biased toward its mechanical roles, some of which are discussed here. PRG4 has been predominantly investigated for its lubricating functions as it is necessary for proper lubrication of articulating cartilage within joints. [25, 28, 29, 36, 37] In the synovial joint, PRG4 is synthesized and secreted into the synovial fluid by chondrocytes and synovial fibroblasts acting primarily as a boundary lubricant between the articulating cartilage-cartilage surfaces of the joint. [28, 38] In pre-clinical animal models of joint inflammation, decreased PRG4 concentration in SF is observed following joint injury (e.g., destabilization) and this is associated with increased damage to the cartilage surface. [39] In patients with acute knee injuries, PRG4 levels in the SF are decreased and return to homeostatic levels typically within a year post-injury. [30] These important lubricating functions of PRG4 are not only found within the joint, as PRG4 deficiency has been found to be associated with increased corneal damage in Prg4 À/À mice in comparison to the wild-type littermates. [5] In the ocular environment, PRG4 is synthesized and secreted by corneal and conjunctival epithelium cells and reduces friction between the cornea and conjunctiva. [5, 6] As stated earlier, much of lubricating ability is thought to be driven PRG4's ability to bind to biological surfaces and through the abundance of negatively charged sugars in O-linked glycosylated mucin rich domain. [40, 41] This has been empirically demonstrated as alterations in glycosylation significantly reduce PRG4's lubricating ability. [25, 40] Systems wide comparison, using shotgun proteomics, of wild-type versus Prg4 À/À mice in models of joint inflammation (e.g., collagen-induced arthritis or DMM injury model) may reveal global protein differences altered by PRG4 expression. Additional experiments using phospho-proteomics to investigate the downstream cell signaling roles of PRG4 validated using conventional molecular approaches would reveal key alterations of phosphorylation during inflammation and inform us of the non-lubricating functions of PRG4.
More recently, the study of PRG4 has moved outside of the joint, with some studies focusing on the role of PRG4 in the pericardium as some CACP patients normally develop pericarditis. PRG4 expressed by pericardial mesothelial cells [10] and secreted in the pericardial fluid in pericardial cavity inhibits adhesion of cardiac myofibroblasts. [7] PRG4 was shown to bind to cell extracellular matrix (ECM) receptors to prevent myofibroblast-mediated collagen synthesis and fiber compaction thus playing a role in scar formation and contraction. [7] In this study, PRG4 was also demonstrated to attenuate transforming growth factor beta 1 (TGF-β1) mediated collagen matrix contraction by myofibroblasts. [7] Much like after joint injury, removal of pericardium fluid during cardiac surgery results in a depression of PRG4 in the pericardial space and this is associated with adhesion formation and inflammation. This phenotype is known to be as least partially dependent on PRG4 levels, as restoration of a PRG4 solution prevented fibrous adhesion, tissue thickening, and inflammatory fluid accumulation. [7] A similar result was also observed in a rat model of intra-abdominal adhesions were restoration of PRG4 levels was shown to limit the development of post-operative adhesions. [42] Initially, the mucin domain was believed to be solely responsible for PRG4's anti-adhesive properties; however, protein denaturation or reduction impair PRG4 anti-adhesive properties suggesting additional function of other domains of PRG4. [35] This implies that PRG4's N-and C-terminal domains must be necessary for it to prevent adhesion dependent cell growth. Similar to experiments suggested above, deletion of specific domains within the N-and/or C-terminal regions of PRG4 and expose of these regions to Prg4
À/À cells and/or mice using fibrotic and/or adhesion models would expand our knowledge of the functions for these domains and PRG4 as a whole. These domains are also essential to PRG4's adhesion ability to cartilage, as reduction and alkylation of PRG4 decreased its ability to bind bovine articular cartilage. Additional studies have explored this further, demonstrating that for PRG4 to act as a boundary lubricant proper globular domains folding is essential as lubrication is lost after reduction, alkylation, [1] and chymotrypsin digestion. [26] PRG4 has been found to regulate the growth and survival of cells thereby maintaining homeostasis of the tissue environment. In synovial fluid, PRG4 protects chondrocytes within the articular cartilage by dissipating strain energy induced through movement. [37, 43] It also prevents protein depositions on the cartilage surface which are believed to act as an abrasive material. [35] In synovial joints PRG4 has also displayed anti-proliferative effects on cells by preventing synovial hyperplasia but the precise downstream cell signaling pathways need to be properly characterized. [17, 35] Complementary in vitro and in vivo experimental models focusing on cell death (e.g., caspase, TUNEL) versus cell proliferation (Ki67, BrdU) in the presence and absence of endogenous PRG4 would help define the its role in these biological processes. Rescue experiments (cDNA expression, recombinant protein treatment) would cement its role in these processes. Follow up OMICS based screening approaches would then provide details on the mechanism and pathways regulated by PRG4 in cell death and/or proliferation. Prg4 À/À mice show progressive synovial hyperplasia, cartilage surface fibrillations, and eventually in vivo chondrocyte apoptosis. [37] Such degenerative events are associated with joint pathologies including OA and RA, and PRG4 has been used therapeutically to resolve those effects in pre-clinical models. [18, 39] 5. PRG4 Interactions With Cell Surface Receptors During Immune Response cell surface receptors of neutrophils [19] and macrophage. [15, 44] In the presence of pro-inflammatory cytokines such as interleukin-1β (IL-β) and tumor necrosis factor α (TNFα), the expression of PRG4 in cartilage (ex vivo) is significantly decreased. In vivo, following a joint injury (in pre-clinical and clinical models), decreased PRG4 levels in the SF coincides with increases in inflammatory cytokines. As levels of the inflammatory signals diminish, PRG4 expression reverts to normal levels over a 12-month period. [30] These suggests that PRG4 is regulated by the inflammatory response, typically in a negative fashion, and once inflammation has subsided, PRG4 returns to homeostatic levels
CD44 is a ubiquitous cell surface receptor involved in cell-cell interactions, cell adhesion, and migration; and at least one isoform of CD44 is expressed on nearly every cell type within the body. Ligands of CD44 include hyaluronic acid (HA), proteases including the matrix metalloproteinases (MMPs) [45, 46] and ECM components including collagen, fibronectin, and laminin. [33, 47] Both CD44 and HA have been previously implicated in a number of chronic inflammatory disease including OA and RA. Furthermore, CD44 is known to regulate NF-κB activity and is a downstream target of the NF-κB signaling pathway. It has been recently demonstrated that PRG4 is able to directly bind to CD44 and that Prg4
À/À synoviocytes demonstrate enhanced nuclear NF-κB (p50 and p65) in comparison to wild-type counterparts. [33] In a rescue experiment, addition of PRG4 to this system reduced nuclear level of NF-κB in a CD44 dependent manner. [33] In vivo, rats subjected to the DMM surgery experienced a reduction and re-localization of their PRG4 in comparison to the non-surgery control, this was coupled with an increase in NF-κB staining within adjacent chondrocytes. This effect can be reversed with an intraarticular injection of recombinant PRG4, providing further evidence of the relationship between PRG4 and the inflammatory signaling cascade (Figure 1) . The broader implication of CD44-PRG4 interact remains unclear and it would be of interest to examine the signaling mechanism of this interaction and if PRG4 can bind immune cells in a CD44 dependent manner. If so, it would be possible to PRG4 to effectively "coat" immune and/or other CD44 positive cells blocking additional cell surface receptors that may play roles in the inflammatory response and/ or other signaling pathways. Additionally, determining what domain or amino acids in PRG4, through mutation studies, are responsible for binding to CD44 would allow site directed mutagenesis of the PRG4 which would potentially allow us to disrupt CD44-PRG4 interaction while maintaining lubrication. These types of experimental approaches would provide further insight into dissecting the lubricating and inflammatory functions of PRG4.
Toll-like receptors (TLRs) are expressed on immune sentinel cells such as macrophages and dendritic cells and they recognize, and are activated by, structurally conserved molecules in bacteria, viruses, and certain endogenous ligands. [48] Individual TLRs recognize specific/distinct domains known as pathogen-associated microbial patterns (PAMPs), which are expressed by pathogens; or danger-associated molecular patterns (DAMPs/Alarmins) that are released from necrotic/dying cells and/or damaged tissue. [49] PAMPs include bacterial components such as lipopolysaccharide (LPS), flagellin, bacterial DNA, and viral double-stranded RNA. DAMPs include intracellular proteins and protein fragments from the extracellular matrix. [50] Stimulation of TLRs by either PAMP's or DAMP's initiates signaling cascades leading to the activation of NF-κB through both MyD88-dependent and -independent pathways [51, 52] leading to a variety of cellular responses including the production of pro and/or anti-inflammatory cytokines. [52] Two recent studies have demonstrated that PRG4 is able to bind with TLR-2, -4, and -5 resulting in NF-κB activation and an alteration in cytokine/chemokine secretion by human synovial fibroblasts which was independent of CD44/HA signaling. [16, 18] Instead, TLRs interactions with PRG4 are believed to keep the cell in a homeostatic state as PRG4 treatment in TLR-2, -4, and -5 expressing cells with PAMP's specific to each receptor elicited a distinct inflammatory response in the presence versus absence of exogenous PRG4. [18] Furthermore, the results of this study suggested that PRG4 does not "coat" the surface of fibroblasts or completely block the TLR receptors since partial signaling through TLRs was still observed in the presence of PRG4. Using co-immunoprecipitation experiments between PRG4 and TLR-2, -4, or -5 using pull-down antibodies before being visualized by western blotting would further support a biological interaction between PRG4 and TLRs. Since knockout mice exist for most if not all of the known TLRs and MyD88, a number of in vivo experiments could be imagined that would test the specificity and/or redundancy of PRG4-TLR interactions and the downstream immune/inflammatory signals of these interactions. One surprising outcome of an earlier study was than PRG4 can bind to TLR9 which is an intracellular TLR. Since PRG4 is a secreted molecule, it would be of interest to confirm that PRG4 can be internalized by multiple cell types [44] and if so, does it directly interact with TLR9 which is known to preferentially bind DNA. In addition, the interaction of PRG4 with TLRs on the synovial fibroblasts appeared to keep the cells in a homeostatic state since when TLR expression on the cells were knocked down, the cells exhibited a pro-inflammatory phenotype even in the presence of PRG4. [18] Additional in vitro and in vivo studies examining the interaction between PRG4 and TLRs would be essential to elucidate the signaling mechanisms supporting in these observations. Specifically, it would be of interest to determine the signaling cascades downstream of TLR 2, 4, and 5 in response to PRG4 treatment and if this was MyD88-dependent/-independent. If MyD88-dependent, then MyD88 knockout animals in a PRG4 conditional knockout background could be used to investigate the consequence of disruption of this pathway in distinct cells/tissues and the implications this may have on normal physiology and disease initiation/progression. PRG4 has been found to co-localize with L-selectin on the surface of peripheral and synovial polymorphonuclear neutrophils (PMNs) at their resting state. [19] Presence of sialylated and sulfated structures on mucin domain of PRG4 is assumed to contain epitopes that interact with L-selectin. [19] This result is both consistent and essential for our hypothesis as neutrophils are among the first responders to sites of inflammation. [53, 54] The migration of neutrophils from the circulation to the site of inflammation is controlled by interaction with the vascular epithelium and L-selectin has been demonstrated to be essential www.advancedsciencenews.com www.bioessays-journal.com for neutrophils to roll along the endothelium in the initiation phase of the adhesion cascade. [55] Furthermore, the results of the PRG4-L-selectin study suggest that PRG4 must interact with other receptors, yet unidentified, on PMNs as after the activation of PMNs by TNFα (which is known to release L-selectin from PMNs), some PRG4 is retained on the PMN surface. [19] In circulation, the presence of L-selectin tethered PRG4 must compete with either L-selectin ligands or other receptors, thus influencing the rolling, adhesion, and eventual migration of leukocytes into/out of the vascular system. The results of this study strongly support the idea that PRG4 "buffers" the inflammatory response as PRG4 coated PMNs could be hypothesized to be less sensitive and responsive to inflammatory factors present in their environment. Only when the cells were exposed to high levels of TNFα did this trigger the release of the majority of surface associated PRG4 from the PMNs allowing the cell surface receptors present on the PMNs to become fully sensitive to their inflammatory environment. Further in vitro experiments should be conducted on PMNs derived from wildtype and L-selectin knockout mice to determine the signaling mechanism involved in PRG4-L-selectin interaction and how this is impacted by TNFα and/or other pro-inflammatory cytokines. PRG4 could be acting as a gatekeeper to the effects of fully activated PMNs, thus, preventing minor stimulation to initiate an unnecessary inflammatory response. Once the stimulus overcomes this threshold kept in check by PRG4, a Figure 1 . PRG4 localization in articular cartilage is negatively associated with NF-κB staining in cartilage post-DMM. In normal rat cartilage (left panels), PRG4 staining is observed in the superficial layer, with minimal NF-κB staining in the adjacent chondrocytes. Post-DMM, PRG4 (green) surface staining is disrupted, and this is associated with increased NF-κB (red) staining in the adjacent chondrocytes (middle panels). If recombinant PRG4 is introduced into the post-DMM rat joint, surface staining of PRG4 is restored with a concurrent decrease in NF-κB staining (right panels). DAPI (blue) nuclear stain, scale bars equal 50 μm.
www.advancedsciencenews.com www.bioessays-journal.com shift in the "coating" functions may occur and an inflammatory cascade takes place. If a PRG4 surface coating keeps PMNs from responding to background levels and minor fluctuations in proinflammatory factors in their environment, this would strengthen the hypothesis presented in this paper. Furthermore, it would be of interest to determine if PMNs from Prg4 À/À mice are more sensitive to inflammatory stimuli, potentially leading to false starts in the response of PMNs. If this is the case, then many of the phenotypes observed in Prg4 À/À mice (e.g., joint damage, pericarditis) may be associated with increased numbers of PMNs (under supposed homeostatic conditions) comparted with wild-type controls.
In addition to aforementioned inflammatory cytokines IL-1β and TNF-α, other inflammatory mediators including IL-6, IL-8, vascular endothelial growth factor (VEGF), monocyte chemoattractant protein (MCP)-1/CCL2, and epidermal growth factor (EGF) have been found to be inversely correlated to PRG4 expression. [56] Following total joint arthroplasty, the levels of inflammatory cytokines (IL-1β, TNF-α IL-6, IL-8, VEGF, MCP-1, and EGF) were found to be higher in blood plasma of the patients comparing to the healthy control while the level of PRG4 was diminished; however, no information was provided from these patients pre-surgery. [56] 
Transcriptional and Proteolytic Regulation of PRG4
Alternative splicing of PRG4 exons results in different isoforms of PRG4. [4] Isoform lacking exon 3, which is believed to be critical to disulfide bond, has recently been reported [57] and interaction of PRG4 with different cell surface receptors and extracellular components may be impaired due to alternative splicing. Tertiary and quaternary folding structures of PRG4 are necessary for its biological function although additional experiments are needed in in vivo to determine whether only the monomeric form or also the covalent forms of PRG4 play a physiological role. [25] Isoforms lacking exon 4 or 5 shows an alteration in binding efficiency to heparin or the ECM. [57] Alternative splicing of the PRG4 gene is also found to be regulated by several growth factors including TGF-β1. [23, 57] Growth factor regulation of splicing, especially the rapid changes in splicing due to phosphorylation of factors controlling splicing has been reported. [58] However, there is still limited information about the roles and interaction of different PRG4 isoforms with cartilage and immune cells in vivo.
Inflammatory cytokines contribute to increased synthesis of multiple proteases. In OA and RA, IL-1β induced overexpression of proteases including MMPs, [59, 60] neutrophil elastase, and cathepsin B coinciding with a reduction in the level of PRG4. [30, 61] Thus, do pro-inflammatory cytokines directly affect expression of PRG4 or they induce protease which in turn cleave and or shed off PRG4 altering its functionality? Previous studies demonstrated that PRG4 is a substrate of MMP-1, MMP-7, neutrophil elastase, plasmin, cathepsin B, [62] and cathepsin S. [14] Although the degradation of PRG4 by cathepsin S was associated with its diminished lubrication, [14] we propose that cleaved PRG4 fragments may interact with cell surface receptors of corneal and conjunctival epithelium cells would affect the inflammatory response. Coincubations of these proteases with PRG4 followed by Nterminal labeling of neo-N-termini (cleavage site labeling) with formaldehyde and an in-gel trypsin digest experiment run on a liquid chromatography (LC) tandem mass spectrometer (MS/ MS) would reveal the precise cleavage sites of PRG4 by each of these proteases. Additionally, neo-epitope antibodies could be raised to these cleavage sites to visualize with immunohistochemistry or western blotting the detectable PRG4 fragments in mouse models of inflammation or human inflammatory disease biopsies. This would further support the disease pathology as previous literature shows that receptor-ligand interaction of CD44 and toll like receptors (TLRs) have different effects based on ligand size. [63] Additionally, post-translational cleavage of the hemopexin-like domain (C-terminal) of PRG4 by subtilisin-like proprotein convertase (SPC) is thought to be essential to protein function. [22] Furthermore, disease causing mutation that removes the last eight amino acids of the protein, including a cysteine residue required for disulfide bond formation in PRG4 disrupts SPC mediated cleavage. [22] Still, little is known about the effect of proteolysis on PRG4 and how fragments of PRG4 impact cell signaling during the initiation and resolution of inflammation.
Duality of PRG4: Lubrication and Regulator of Inflammation
Inflammation is a necessary response in pathological disease mechanisms but become harmful when not resolved in an appropriate cell/tissue/organ/organismal specific timeframe. For example, the liver has a unique potential to regenerate after tissue damage (a process regulated by inflammatory mediators) and plays an important role in regulating blood sugars and lipid level. [64] Such inflammatory cascade is mediated through cytokines and chemokines which can be either pro-and antiinflammatory under different circumstances. During homeostasis, the marginal effects of pro-inflammatory cytokines are buffered by anti-inflammatory cytokines thereby keeping a "background" inflammation. When the levels of pro-inflammatory cytokines increase beyond the threshold level following an injury or infection, anti-inflammatory agents are no longer able to maintain homeostasis, which in turn become harmful.
PRG4 acts as an anti-inflammatory agent by buffering proinflammatory effects keeping the pro-inflammatory mediators in check and interfering with their interactions with receptors. PRG4 coats both immune (e.g., macrophage, neutrophils) and non-immune (e.g., fibroblast and epithelium cells) cells through interaction with a number of surface receptors including CD44, [33] TLRs, [16, 18] and L-selectin [19] and potential, other unknown receptors (Figure 2) . Covalent complexes of PRG4 can extend over several cell receptors to "coat" the microenvironment although additional evidence is needed to support this in vivo. We hypothesize that PRG4 interactions with the receptors block the available receptors of pro-inflammatory cytokines, thus preventing cytokines downstream signaling (antagonism). Our hypothesis is supported by current studies where the level of PRG4 shows an inverse relationship with proinflammatory cytokines including IL-1β, TNFα [30] while www.advancedsciencenews.com www.bioessays-journal.com
proportional relationship with anti-inflammatory mediators including transforming growth factors (TGF) β and interferon (INF)-γ. [65] During an injury or infection, immune cells become activated and secrete various proteases that cleave structural and ECM proteins. We hypothesize that at the site of inflammation, upregulated proteolytic activity from cathepsins, ADAMTSs, ADAMs, and MMPs secreted by the activated immune cells in response to pro-inflammatory cytokines (IL-1β and TNF-α) cleave and remodel PRG4. Peptides generated through proteolysis may trigger an inflammasome response [44] causing a more pronounced inflammatory cascade (Figure 2 ). Downstream signal of inflammatory receptors interacting with their ligands is proportional with their size, therefore, we hypothesize that these PRG4 peptide products alter the inflammatory cascade. For example, in case of fibronectin, cleavage of fibronectin by proteases further exposes its V-region, which contains the site for α4βa integrin binding. [66] Buffering ability of PRG4 is restored when pro-inflammatory cytokines diminish to the threshold level ( Figure 3) . In acute inflammation where resolution occurs, levels of the PRG4 are reestablished thereby returning the homeostatic environment. In unresolved chronic inflammation, PRG4 levels are dysregulated, pro-inflammatory cytokines are persistent and PRG4 decreases. What are the regulatory mechanisms that maintain the level of PRG4 and pro-inflammatory cytokines at equilibrium during the resolution of acute inflammation but not in unresolved chronic inflammatory diseases? Proposed regulation of the inflammatory environment by PRG4. In homeostasis, PRG4 buffers the biological system against small changes in pro-inflammatory cytokine expression (e.g., spikes in background levels). Once a threshold of inflammation has been broken (e.g., infection/injury/etc), pro-inflammatory mediators increase in the environment, inducing a concurrent decrease in PRG4 expression. PRG4 levels return to normal levels only after pro-inflammatory mediators have returned to baseline levels, restoring the system to homeostasis.
www.advancedsciencenews.com www.bioessays-journal.com PRG4 altered expression and function are indeed associated with both acute and chronic diseases including OA, RA, Sjogren syndrome and CACP, however, these observations are based on the mechanical role of the PRG4. We hypothesize that cells respond to an injury or infection by releasing proinflammatory and proteases which in turn cleaves PRG4 thereby facilitating cell surface leading to a worse proinflammatory trigger. Moreover, PRG4 fragments potentially initiate a distinct inflammatory signaling trigger with Lselectin, CD44, TLRs, and other unidentified receptors (Figure 2) . Therefore, PRG4 may participate in perpetuating chronic inflammation. Identifying these novel signaling signatures of PRG4 using quantitative shotgun and phosphoproteomics will enable us to better understand chronic inflammation on a global scale.
Conclusion and Future Perspectives
Post-translational modifications of PRG4 is dysfunctional in inflammation and we are only beginning to understand these novel roles. Deciphering how full-length, monomer, covalent complexes, and fragments of PRG4 impacts cell signaling and how the transcriptional repression is regulated will lead to a better understanding of this ECM protein with diverse physiological roles. Many roles of PRG4 at homeostasis have been lost in the background noise but became dramatic during the resolution phase of inflammation within the joints and the eye as evidenced by the decreased in lubrication and dysregulation of inflammation in Prg4 À/À mice as compared to the wild-type counterparts. What is the tipping point for PRG4 to "sense" a physiological shift altering its function, especially when post-translation modifications are deeply affecting PRG4? How sensitive and affected is PRG4 to proteolysis and de-glycosylation? Many proteases can process different domains of PRG4 but redundancy is often too easy an excuse to understand these cleavages and their effects on inflammation. Localization of proteases (secreted vs. cell surface), glycolysis, cell surface receptors and the type of immune cells at a specific site all impact the state of PRG4, yet little is known about the driving mechanism observed in various pathologies. All these newly identified functions of PRG4 pave the way for a new era for the investigation of PRG4's regulation and functions in inflammatory diseases.
